Clinical Study

Two Oral Midazolam Preparations in Pediatric Dental Patients: A Prospective Randomised Clinical Trial

Katayoun Salem, Shaqayegh Kamranzadeh, Maryam Kousha, Shahnaz Shaeghi, and Fatemeh AbdollahGorgi

1Department of Pediatric Dentistry and Oro-Maxillofacial Developmental Disease Research Center, Faculty of Dentistry, Guilan University of Medical Sciences, Rasht 4194173774, Iran
2Guilan University of Medical Sciences, Rasht, Iran
3Department of Pediatric Psychiatry, Shafa Hospital, Guilan University of Medical Sciences, Rasht, Iran
4Department of Pediatric Anesthesiology, Mofid Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
5Medical Research Development Center, Mofid Children’s Hospital, Shahid Beheshti University of Medical Sciences, Iran

Correspondence should be addressed to Katayoun Salem; katayoun.salem@gmail.com

Received 5 December 2014; Accepted 27 April 2015

1. Introduction

Dental fear/anxiety and behavior management problems in pediatric patients are two major aspects of uncooperativeness in pediatric dentistry. Whilst Psychological techniques are the cornerstone of behavior management in pediatric dentistry, a number of children cannot cope with dental treatment using these techniques alone. Pharmacological methods have been used as an adjunct to enhance child cooperativeness and facilitate dental treatment [1, 2]. The primary aim of mild and moderate pharmacological sedation in pediatric dentistry is to modify the patient’s behavior to an extent that allows applying behavior management techniques [1]. Evidence for best choice of sedative agents in children is still incomplete [2]; however, midazolam, a short-acting benzodiazepine, has been extensively used due to its therapeutic index and wide margin of safety [3–9]. Since oral dosage form of midazolam is not commercially available in many countries, therefore injectable midazolam in mixture with a flavoring agent, to mask the undesirable taste and adjust the pH, briefly known as extemporaneous form (EF) has been used as an alternative [3, 7].

Despite extensive administration of EF preparation, there is no consensus on its effectiveness [2]. Therefore the aim of this study was to

(i) evaluate and compare the safety and efficacy of two midazolam oral preparations: “EF midazolam” versus “commercially prepared midazolam syrup” in pediatric dental patients by measuring physiological parameters and behavioral scales including North Carolina and Houpt behavioral scales. The latter ones evaluate the level of consciousness and cooperative-ness in sedated patients.
the injectable solution of midazolam hydrochloride (Ampule 15 mg/3 mL Midamax, Tehran Shimi, Iran) in combination with the same volume of concentrated viscous orange syrup according to their age. The pH of final EF preparation was 3.7 and the commercial preparation’s pH was equal to 4. Both pH values were determined by automated pH meter (Acorn Ion 6 Meter). Drugs were administrated by a dental nurse who was unaware of the study design, using a needleless syringe placed in the lower buccal vestibule. After administration of midazolam, the patients remained under supervision in a quiet place. Thirty minutes after administration, children were transferred to dental operatory in accompany of their parents. Parents were asked to leave the operatory during the treatment session to eliminate any potential impact of parent’s presence on child’s behavior. All participants received similar restorative treatments including topical anesthetic gel (Benzocaine 10%) and pulp therapy followed by restoration of the tooth which included either fillings or stainless steel crowns. The maximum dose of local anesthesia was limited to 4 mg/kg. Treatment was planned to be accomplished in maximum thirty minutes and any type of physical restraints was not used.

2.2. Behavior Assessment. Behavior was videotaped and rated by a trained and calibrated examiner who was blind to the study design using two behavioral measures: North Carolina rating scale to evaluate behavior preoperatively and during critical moments of treatment including injection and cavity preparation (Table 3) and Houpt sedation rating scale to determine the level of sedation according to degree of sleep, crying, movement, and finally an overall appraisal of behavior through the treatment course (see Definition of Houpt sedation rating scale) [11]. The examiner was the senior dental student who was trained and calibrated via examination of five patients prior to study. The Cohen Kappa for intra-examiner reliability was 8.9.

**Definition of Houpt Sedation Rating Scale Is as Follows [11]**

**Rating Scale for Sleep**

(1) fully awake, alert,
(2) drowsy, disoriented,
(3) asleep.

**Rating Scale for Crying**

(1) hysterical crying that demands attention,
(2) continuous, persistent crying that makes treatment difficult,
(3) intermittent, mild crying that does not interfere with treatment,
(4) no crying.

**Rating Scale for Movement**

(1) violent movement interrupting treatment,
Table 2: Frequency of exhibited behavior according to North Carolina (NC) behavior rating scale.

| Evaluation time   | Group | Quiet \( n (%) \) | Annoyed \( n (%) \) | Upset \( n (%) \) | Wild \( n (%) \) | \( P \) value* |
|-------------------|-------|-------------------|---------------------|-----------------|----------------|--------------|
| Child arrival     | Syrup | 0 (0)             | 27 (61.4)           | 14 (31.8)       | 3 (6.8)        | \( P = 0.43 \) |
|                   | EF    | 0 (0)             | 28 (63.6)           | 10 (22.7)       | 6 (13.6)       |              |
| Injection         | Syrup | 17 (38.6)         | 20 (45.5)           | 7 (15.9)        | 0 (0)          | \( P = 0.52 \) |
|                   | EF    | 21 (41.7)         | 17 (38.6)           | 6 (13.6)        | 1 (2.3)        |              |
| Cavity preparation| Syrup | 24 (54.5)         | 14 (31.8)           | 6 (13.6)        | 0 (0)          | \( P = 0.23 \) |
|                   | EF    | 19 (43.2)         | 16 (36.4)           | 7 (15.9)        | 2 (4.5)        |              |
| Total             | 88    | 43 (48.9)         | 31 (35.2)           | 12 (13.6)       | 2 (2.3)        |              |

*Friedman test.

Table 3: Definition of North Carolina rating scale [12].

| Behavior | Definition                                                                 |
|----------|---------------------------------------------------------------------------|
| Quiet    | Patient is quiet or sleeping with only extraneous, inconsequential movements |
| Annoyed  | Patient is cooperative for treatment but with 1 or 2 undesirable behaviors  |
| Upset    | Patient noticeably disturbed, with 2 to 3 undesirable behaviors present, making treatment difficult |
| Wild     | Patient extremely defiant with presence of all undesirable behaviors making treatment extremely difficult |

* Undesirable behavior includes crying, screaming, head movement, torso movement, and foot movement.

(2) continuous movement making treatment difficult,
(3) controllable movement that does not interfere with treatment,
(4) no movement.

Rating Scale for Overall Behavior

(1) aborted no treatment rendered,
(2) poor treatment interrupted, only partial treatment completed,
(3) fair treatment interrupted, but eventually all completed,
(4) good, difficult, but all treatment performed,
(5) very good some, limited crying or movement, for example during anesthesia or mouth prop insertion,
(6) excellent no crying or movement.

2.3. Physiologic Parameters. Physiologic parameters including heart rate, respiratory rate, oxygen saturation, and blood pressure were monitored continuously during treatment using operating room design monitors (Massimo Set, Alborz B5 Saadat, Iran) through the course of treatment and every 15 minutes. Physiological parameters were recorded at baseline and at every 15 minutes. The parameters rated at the time of arrival when the child entered the operatory on the day of study for sedation appointment and before any drug administration. The measurements repeated at the beginning of treatment and then every 15 minutes. Hypoxemia was determined as oxygen saturation beyond 93% (except during crying) and \( \text{Spo2} < 90\% \) was considered as apnea [12].

2.4. Data Analysis. Data were analyzed using Kolmogorov Simonov, independent \( t \)-test, Chi-square, Friedman test, Fisher’s exact test, Mann-Whitney test, repeated measure Greenhouse Geiser, adjustment Bonferroni, backward step-wise multivariate regression, and Mantel-Haenszel common odds ratio by SPSS version 21. Significance level was established at 0.05 in all tests.

3. Results

A total of eighty-eight children including participated in the study. Demographic characteristics of patients are presented in Table 1. There were no statistical differences in age, weight (Independent \( t \)-test \( P = 0.14 \), and \( P = 0.77 \)), and gender (Chi-square \( P = 0.41 \)) between the two groups. Characteristics of participants under and above the age of 60 months in two study groups are presented in Table 2. Participants of syrup and EF groups did not show significant difference in age and gender.

The flow diagram of study participants is presented in Figure 1.

3.1. Rating of Behavior

3.1.1. North Carolina Rating Scale. Table 2 presents the behavior assessments by North Carolina rating scale at important moments of sedation appointments including “before sedation, when the child arrived to operatory at the day of sedation appointment and before any drug administration,” “during injection,” and “cavity preparation.” The worst manifestation of child’s behavior was recorded at each step. All children revealed more calm behavior at the times of injection and cavity preparation in comparison to their behavior at the time of arrival (Friedman test \( P < 0.001 \)).

3.1.2. Houpt Sedation Rating Scale. Figures 2–5 present the age adjusted categories of Houpt Behavior Rating Scale. There were 15 children under the age of 59 months and 73 aged 60 months and older. Ratings of sleep, crying, movement, and overall behavior domains were divided into two-dose (age)
The study design did not contain follow-up session. The study design did not contain follow-up session.

**Enrollment**
- Assessed for eligibility ($n = 95$)
  - Excluded ($n = 3$)
    - Not meeting the inclusion criteria ($n = 2$)
    - Do not comply with treatment plan ($n = 1$)

**Allocation**
- Randomized ($n = 92$)
- Allocated to midazolam syrup ($n = 46$)
  - Received allocated intervention ($n = 44$)
  - Did not receive allocated intervention: reluctant to intake drug ($n = 1$) and hysterial behavior at the time of drug administration and after 30 minutes ($n = 1$)
- Allocated to EF midazolam ($n = 46$)
  - Received allocated intervention ($n = 44$)
  - Did not receive allocated intervention: split out the medication immediately ($n = 2$)

**Follow-up**
- Lost to followup ($n = 0$)
  - The study design did not contain follow-up session
  - The study design did not contain follow-up session

**Analysis**
- Analysis ($n = 44$)
  - Excluded from analysis ($n = 0$)
  - Excluded from analysis ($n = 0$)

*Figure 1: Consort flow diagram of study group.*

Acceptable behavior according to age was observed in 7 and 6 children younger than the age of 5 years and among 33 and 29 children at 5 years of age and older, in syrup and EF groups, respectively (Fisher exact; $P = 0.267$ and $P = 0.261$).

When adjusted for age (48–59 months children versus 60 months and older), the risk that a child displayed acceptable overall behavior after EF midazolam administration was 0.38 times compared to those who received syrup ($OR = 0.388$, SE (0.64) 95% CI: 0.11–1.37; $P = 0.114$) (Mantel-Haenszel common odds ratio estimate).

The overall behavior regardless of age was dichotomized, and two categories of acceptable and unacceptable behavior were determined. The Acceptable behavior was defined as *good*, *very good*, and *excellent*. The unacceptable behavior included: *fair*, *poor*, and *aborted* categories of behavior. Acceptable behavior was observed in 90.9% of syrup and 79.5% of EF, respectively, Chi-square $P = 0.13$.

Stepwise backward regression was used to determine the best predictors of overall sedation success regardless of age.
3.2. Physiologic Parameters. Data on physiological parameters are presented regardless of age classification. Investigated physiologic parameters remained in normal range in both study groups. Up to 20% increase/decrease in normal limits for each age group was considered normal. A detailed explanation of physiological parameters is presented in the following.

3.2.1. Percent of Oxygen Saturation ($SPO_2$). There was no significant difference between two study groups in percent of oxygen saturation: $P = 0.24$ (repeated measure Greenhouse Geiseer). Fluctuation of $SPO_2$ in syrup group was not significantly different from one time to another. In contrast, significant (but within normal) changes in $SPO_2$ were observed between minute 30 and other measurement times among EF group: $P$ values: 0.015, 0.006, and 0.009 for baseline, minute 0, and minute 15, respectively (adjustment Bonferroni test).
3.2.2. Heart Rate. Subjects in group A (syrup) had a higher baseline heart rate in comparison to group B. \( P < 0.01 \), and this pattern continued at all measurement times except minute 0. Intragroup measurements did not show any significant change from baseline to minute 30: repeated measure of Greenhouse \( P > 0.05 \).

3.2.3. Respiratory Rate. Respiratory rate was higher basically and in all other measurements except minute baseline, in group A. There was a mild descending curve from baseline to minute 30 in this group: Mann-Whitney test, \( P = 0.004 \).

3.2.4. Systolic and Diastolic Blood Pressure. The groups were not significantly different. Intragroup measurements revealed significant fluctuations in systolic and diastolic blood pressure in group B: repeated measure of Greenhouse \( P = 0.02 \) and \( P = 0.001 \) for systolic and diastolic pressure, respectively.

Serious adverse effects were not observed during and after sedation appointment. One case of hiccups was observed shortly after drug administration.

4. Discussion

The results of this study indicated that both regimens were safe with reasonable level of sedation acquired. To the best of our knowledge, there are few published studies that have investigated safety and efficacy of midazolam syrup versus orally administered IV midazolam (EF midazolam). In comparison to commercial syrup with IV midazolam in the mixture of Syrpalta (pH = 5), Brosius and Bannister reported higher plasma levels and superior sedative effects from IV midazolam-Syrpalta [13]. Khalil et al. reported less preanesthetic anxiety at 15 minutes and at parental separation in children who received IV midazolam-Syrpalta mixture when compared to those who received the premixed midazolam solution [14].

The effectiveness of EF midazolam over commercial preparations is a controversial issue [2, 5]. Our results did not show a significant difference between two midazolam preparations; however, administration of the commercial syrup increased the chance of overall success when compared to EF preparation. Variability of sweeteners and juices added to IV drug resulted in diversity in pH, viscosity, and pharmacokinetics that may explain this controversy [15–18]. The pH of our oral dosage was 3.7 and the pH of commercially syrup was 4 and fruit juices usually added to midazolam had a pH about 2.8 that can justify the difference in absorption of drug [15, 19]. Mucosal absorption is a pH dependent phenomenon. Increasing the pH from 2.8 (IV formulation) to 4 results in formation of more than 95% of active lipophilic drug or closed ring that is readily absorbable from oral mucosa [13, 14]. Since significant amount of midazolam is absorbed by mucosal membranes of the oral cavity, esophagus, and stomach, pH variability may result in divergent observed responses to midazolam [19]. Another consideration in midazolam absorption is the drug’s viscosity. Viscous preparations are retained in oral environment for longer periods of time that per se increases the local absorption of drug from permeable oral mucosa especially nonkeratinized tissue of buccal mucosa [16, 18, 20, 21]. Relative absorption of drug from direct drainage of oral blood vessels into the jugular vein is another priority over less viscous preparations which lead to better bioavailability of drug [20].

In the present study a dose of 0.5 and 0.2 mg/kg was chosen for children under and over five years of age, respectively, according to a pilot study as well as the previous works on this area [3, 22]. Age effects on dosage requirements have been discussed in the anesthesiology literature [17]. The midazolam dose should be individualized based on patient age, degree of anxiety, and the level of sedation desired [3]. Younger children may need higher doses of the drug for higher hepatic blood flow and metabolism rate [16, 23], in addition to lower expression, distribution, and coupling ability of type A GABA receptors [17]. It appears to be an optimal balance between anxiolytic activity and side effect liability in doses of 0.25 mg to 0.50 mg/kg [3]. We compared all aspects of sedation including sleep, movement, crying, and overall behavior by adjusting the effect of age. Similar results were achieved when the total dose was restricted to decrease the dose in older children. Although midazolam falls in a group of agents with broad margin of safety, lowering the dose may be desirable for decreasing the potential side effects [3, 5]. It may be logical to preserve the higher doses for those who do not respond favorably to lower doses of drug.

Mild and moderate sedation via oral route is an effective, safe, and convenience mode of midazolam administration that may fill the gap between psychological strategies and general anesthesia in many subjects.

More research is needed either by increasing the prescribed dose of drug or by administration of alternative agents in cases of unsuccessful sedations.

5. Conclusion

According to the results of this study EF midazolam preparations in a dose of either 0.2 or 0.5 mg/kg provided safe and effective sedation. Hence, lower doses may be advocated to older children.

Clinical Implications

(a) What is already known is that midazolam is widely used as a safe and effective sedative agent in pediatric sedation. However, oral form of drug is not available in many countries and it is also expensive and not cost effective for occasional use.

(b) What this article adds is that injection formulation can be used for oral administration.

(c) Implications for translation are as follows. This extemopaneous preparation may be effectively used by pediatric dentists and other professionals who work in pediatric area as a safe effective agent in management of uncooperative behavior. In addition, identifying the populations who benefit from this agent can help to target the responders. Further researches can focus on other doses of midazolam or
alternative agents for children with those behavioral characteristics that are not responsive to midazolam.

**Ethical Approval**

Ethical approval was obtained from ethical committee of Guilan University of Medical Sciences reference number 3910354611 and IRCR reference number IRCT201302031861N4.

**Disclosure**

This investigation was based on a dissertation submitted by the second author to the Faculty of Dentistry of the Guilan University of Medical Sciences (GUMS) in Iran, in partial fulfillment of the requirements for receiving a doctoral degree.

**Conflict of Interests**

The authors declare that they have no conflict of interests.

**Acknowledgments**

The study is granted by Deputy of Research, Guilan University of Medical Sciences. The authors also express their appreciation to Mrs. Nastaran Mirfarhadi and dental nurses Mrs. Sarah Ataiee and Mrs. Masoumeh Rahmati for their contribution in blinding and drug administration.

**References**

[1] M. Raadal, S. Lundeberg, and G. Haukali, "Pain, pain control and sedation," in Pediatric Dentistry, A Clinical Approach, G. Koch and S. Poulsen, Eds., p. 54, Blackwell, Singapore, 2nd edition, 2009.

[2] L. Lourenço-Matharu, P. F. Ashley, and S. Furness, "Sedation of children undergoing dental treatment," The Cochrane Database of Systematic Reviews, vol. 3, Article ID CD003877, 2012.

[3] A. Alzahrani and A. Wyne, "Use of oral midazolam sedation in pediatric dentistry: a review," Pakistan Oral & Dental Journal, vol. 32, no. 3, pp. 444–455, 2012.

[4] D. E. Becker and P. A. Moor, "Anxiolytics and sedative-hypnotics," in Management of Pain and Anxiety in the Dental Office, R. A. Dionne, J. C. Phero, and D. E. Becker, Eds., pp. 129–260, W.E. Saunders Company, 1st edition, 2002.

[5] C. Goho, "Oral midazolam-grapefruit juice drug interaction," Pediatric Dentistry, vol. 23, no. 4, pp. 365–366, 2001.

[6] S. F. Malamed, Sedation: A Guide to Patient Management, Chapter 7, C. V. Mosby, Elsevier, San Diego, Calif, USA, 5th edition, 2010.

[7] M. Rosenberg, "Oral midazolam syrup as a safe sedative for pediatric dentistry," Dental News, vol. 7, no. 3, pp. 69–71, 2000.

[8] S. A. Sheta and M. AlSarheed, "Oral midazolam premedication for children undergoing general anaesthesia for dental care," International Journal of Pediatrics, vol. 2009, Article ID 274380, 7 pages, 2009.

[9] S. Wilson and L. Ganzberg, "Pain Reaction control: sedation," in Casamassimo, Fields, Mettigue, Nowak; Pediatric Dentistry, Infancy through Adolescence, p. 115, Elsevier, Beijing, China, 5th edition, 2013.

[10] J. A. Dean, D. R. Avery, and R. E. McDonald, Eds., McDonald and Avery's Dentistry for the Child and Adolescent, Mosby-Elsevier, Shanghai, China, 9th edition, 2011.

[11] M. I. Houpit, R. G. Rosivack, N. Rozenfarb, and S. R. Koeningsberg, "Effects of nitrous oxide on chloral hydrate sedation of young children," Anesthesia Progress, vol. 33, no. 6, pp. 298–302, 1986.

[12] M. M. Sheronan, D. C. Dilley, W. J. Lucas, and W. F. Vann, "A prospective study of 2 sedation regimens in children: chloral hydrate, meperidine, and hydroxyzine versus midazolam, meperidine, and hydroxyzine," Anesthesia Progress, vol. 53, no. 3, pp. 83–90, 2006.

[13] K. K. Brosius and C. F. Bannister, "Midazolam premedication in children: a comparison of two oral dosage formulations on sedation score and plasma midazolam levels," Anesthesia & Analgesia, vol. 96, no. 2, pp. 392–395, 2003.

[14] S. N. Khalil, H. N. Vije, S. S. Kee, A. Farag, E. Hanna, and A. Z. Chuang, "A paediatric trial comparing midazolam/syrupal mixture with premixed midazolam syrup (Roche)," Paediatric Anaesthesia, vol. 13, no. 3, pp. 205–209, 2003.

[15] B. Isik, O. Baygin, and H. Bodur, "Effect of drinks that are added as flavoring in oral midazolam premedication on sedation success," Paediatric Anaesthesia, vol. 18, no. 6, pp. 494–500, 2008.

[16] K. Jain, B. Ghai, A. K. Saxena, D. Saini, and N. Khandelwal, "Efficacy of two oral premedicants: midazolam or a low-dose combination of midazolam-ketamine for reducing stress during intravenous cannulation in children undergoing CT imaging," Paediatric Anaesthesia, vol. 20, no. 4, pp. 330–337, 2010.

[17] Z. N. Kain, J. N. MacLaren, B. C. McClain et al., "Effects of age and emotionality on the effectiveness of midazolam administered preoperatively to children," Anesthesiology, vol. 107, no. 4, pp. 543–552, 2007.

[18] L. D. Mishra, G. K. Sinha, P. B. Rao, V. Sharma, K. Satya, and R. Gairola, "Injectable midazolam as oral premedicant in pediatric neurosurgery," Journal of Neurosurgical Anesthesiology, vol. 17, no. 4, pp. 193–198, 2005.

[19] J. Zhang, S. Niu, H. Zhang, and J. B. Streisand, "Oral mucosal absorption of midazolam in dogs is strongly pH dependent," Journal of Pharmaceutical Sciences, vol. 91, no. 4, pp. 980–982, 2002.

[20] A. H. Shojaei, "Buccal mucosa as a route for systemic drug delivery: a review," Journal of Pharmacy & Pharmaceutical Sciences, vol. 1, no. 1, pp. 15–30, 1998.

[21] M. F. Levine, I. A. Spahr-Schopfer, E. Hartley, J. Lerman, and B. MacPherson, "Oral midazolam premedication in children: the minimum time interval for separation from parents," Canadian Journal of Anaesthesia, vol. 40, no. 8, pp. 726–729, 1993.

[22] L. Saarnivaara, L. Lindgren, and U.-M. Klemola, "Comparison of chloral hydrate and midazolam by mouth as premedicants in children undergoing otolaryngological surgery," British Journal of Anaesthesia, vol. 61, no. 4, pp. 390–396, 1988.

[23] C. J. CotE, J. Lerman, R. M. Ward, R. A. Lugo, and N. Goudosouzian, "Pharmacokinetics and pharmacology of drugs used in children," in A Practice of Anaesthesia for Infants and Children, C. J. CotE, J. Lerman, and I. D. Todres, Eds., Elsevier, 4th edition, 2008.